Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Britain Courts Anthropic Amid US Defense Department Dispute 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
NEW YORK, Nov. 29, 2016 -- Ovid Therapeutics, a privately-held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced its participation in two upcoming investor conferences:
- Citi 2016 Global Healthcare Conference
Members of the Company’s management team will participate in one-on-one meetings with investors on Wednesday, December 7, 2016, at the Lotte Palace Hotel in New York, NY.
- BMO Capital Markets 2016 Prescription for Success Healthcare Conference
Yaron Werber, M.D., chief business and financial officer of Ovid, will present on Wednesday, December 14, 2016, at 4:40 p.m. ET at the InterContinental Barclay Hotel in New York, NY.
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a privately held, New York-based, biopharmaceutical company committed to transforming the lives of patients with orphan diseases of the brain. Ovid focuses on patients and their unmet medical needs. Using the significant operational, product development, and business development experience of its management team, Ovid aims to become a leading neurology company, with multiple products and a rich pipeline, coupled with compelling research and development. Ovid has raised $80M in financings led by Fidelity Management and Research Company and including Cowen Private Investments, Sanofi-Genzyme BioVentures, Tekla Capital Management, Sphera Global Healthcare Fund, Jennison Associates, Redmile Group, DoubleLine Equity Healthcare Fund, and Cormorant Asset Management, as well as additional blue chip mutual funds and leading life sciences investors.
Contacts Investors: Burns McClellan Steve Klass, 212-213-0006 [email protected] Media: Pure Communications, Inc. Katie Engleman, 910-509-3977 [email protected]
